When to Convert from Aveir VR Leadless Pacemaker to LBBAP
Clinical Question
When would you recommend stopping an Aveir VR leadless pacemaker and placing a LBBAP pacemaker, given the following scenario:
- Device longevity: 20 months of functioning (40% through expected lifespan)
- Battery expectancy: 5 years total (60% remaining)
- Output parameters: 4.0V @ 0.4ms
- Complications: Usual nocturnal non-capture episodes (common in single-chamber leadless pacemakers)
- Symptoms: Patient discomfort due to atrioventricular dyssynchrony
Current Situation Analysis
Device Performance Status
| Parameter |
Current Status |
Clinical Significance |
| Device Age |
20 months (40% of expected life) |
Still 60% battery life remaining |
| Electrical Output |
4.0V @ 0.4ms |
Normal, adequate capture margins |
| Nocturnal Performance |
Recurrent non-capture episodes |
Inherent limitation of single-chamber leadless technology |
| AV Synchrony |
Absent (VVI pacing) |
Causing symptomatic dyssynchrony |
Recommendation for LBBAP Conversion
Primary Recommendation
I recommend considering LBBAP conversion NOW or in the near term based on the presence of symptomatic AV dyssynchrony and recurrent nocturnal complications.
Strong Indications for Immediate Conversion
1. Symptomatic AV Dyssynchrony:
- Significant exercise intolerance
- Heart failure symptoms
- Reduced ejection fraction
- Pacemaker syndrome (fatigue, dyspnea, presyncope)
- Progressive decline in functional capacity
2. Nocturnal Pacing Issues Causing Clinical Problems:
- Symptomatic nocturnal bradycardia
- Sleep disturbances affecting overall health
- Documented syncope or presyncope episodes
- Evidence of hemodynamic compromise during sleep
- Recurrent emergency department visits
3. Progressive Left Ventricular Dysfunction:
- Any decline in ejection fraction from baseline
- New regional wall motion abnormalities
- Elevated BNP/NT-proBNP with upward trends
- Echocardiographic evidence of ventricular remodeling
Consider Waiting If:
- Symptoms are mild and manageable with conservative measures
- Patient is elderly with limited life expectancy (<3-5 years)
- High surgical or procedural risk factors present
- Strong patient preference after thorough informed discussion
- Stable hemodynamics with preserved LV function
- Minimal pacing burden (<20%)
Clinical Decision Framework
The 20-Month Timeframe Consideration
Economic vs. Clinical Considerations:
- Device still has 60% battery life remaining (economic factor)
- However, you're not "wasting" the device if patient health improves significantly
- Earlier conversion prevents cumulative deleterious effects of chronic AV dyssynchrony
- The cost of 3+ years of suboptimal physiology may outweigh device replacement costs
Key Principle:
Don't sacrifice 3+ years of suboptimal physiology to maximize device battery utilization. Patient quality of life and clinical outcomes take precedence over device economics.
Understanding Aveir VR Limitations
The Aveir VR's limitations are inherent to single-chamber leadless pacemaker technology, not a programming issue that can be resolved:
- Nocturnal non-capture: Related to increased vagal tone, positional changes, and circadian variation in capture thresholds
- AV dyssynchrony: VVI pacing mode cannot provide atrial sensing or AV synchrony
- Rate response limitations: Accelerometer-based rate response may not match physiologic demands
- These issues will not improve with time or programming adjustments
Practical Approach: When to Act
Recommend LBBAP Conversion NOW if ANY of These Apply:
- NYHA Class II or higher symptoms related to pacing
- LVEF decline from baseline or currently below 50%
- Documented nocturnal events causing symptoms or requiring intervention
- Significant quality of life impairment reported by patient
- High pacing burden (>40%) with concerns about long-term RV pacing effects
- New or worsening heart failure symptoms
- Patient's strong preference for improved pacing physiology
LBBAP Advantages Over Aveir VR
| Feature |
Aveir VR |
LBBAP |
| AV Synchrony |
❌ Absent |
✅ Preserved |
| Physiologic Activation |
❌ RV apical activation |
✅ Near-normal His-Purkinje system |
| Nocturnal Capture Stability |
⚠️ Variable, prone to non-capture |
✅ Stable with safety margins |
| QRS Duration |
⚠️ Typically widened |
✅ Narrow or minimally widened |
| Rate Response |
⚠️ Accelerometer-based |
✅ Atrial-based (physiologic) |
| Programming Flexibility |
⚠️ Limited |
✅ Full dual-chamber options |
| Long-term LV Function |
⚠️ Risk of pacing-induced cardiomyopathy |
✅ Preserved or improved |
Clinical Decision Algorithm
Step-by-Step Decision Process
Step 1: Assess Symptoms
- Is the patient symptomatic from AV dyssynchrony? → If YES, proceed to conversion
- Are nocturnal events causing clinical problems? → If YES, proceed to conversion
Step 2: Evaluate Cardiac Function
- Has LVEF declined? → If YES, proceed to conversion
- Any new wall motion abnormalities? → If YES, proceed to conversion
- Elevated or rising BNP? → If YES, consider conversion
Step 3: Consider Pacing Burden
- Pacing burden >40%? → Consider conversion
- Consistent nocturnal pacing dependency? → Consider conversion
Step 4: Risk-Benefit Analysis
- Life expectancy >5 years? → Favors conversion
- Low surgical risk? → Favors conversion
- Patient preference for improved QOL? → Favors conversion
Final Recommendation for This Case
My Clinical Recommendation
Given the combination of:
- ✓ Symptomatic AV dyssynchrony ("usual discomfort")
- ✓ Recurrent nocturnal non-capture episodes
- ✓ Adequate remaining health span to benefit from superior pacing physiology
- ✓ Only 20 months device age (not near end of life)
I would recommend proceeding with LBBAP conversion without waiting for battery depletion.
Rationale: The physiological benefits of physiologic pacing and elimination of nocturnal issues significantly outweigh the economic consideration of remaining device longevity. The Aveir VR has served its purpose during the initial implant period, but the patient's clinical course now clearly indicates a need for dual-chamber or physiologic pacing capability that leadless technology cannot provide.
Patient Counseling Points
Discussion Points for Shared Decision-Making
- Current device limitations: Explain that nocturnal non-capture and AV dyssynchrony are inherent to single-chamber leadless technology and cannot be resolved with programming
- Benefits of conversion: Improved exercise tolerance, better sleep quality, restoration of AV synchrony, more physiologic pacing
- Procedural risks: LBBAP implantation risks (septal perforation, lead dislodgement, infection) vs. continuing with suboptimal pacing
- Long-term outcomes: Potential prevention of pacing-induced cardiomyopathy with LBBAP
- Alternative options: Traditional dual-chamber pacemaker, His-bundle pacing, continued conservative management
- Economic considerations: Device replacement costs vs. quality of life improvement over remaining years
Post-Conversion Expectations
Expected improvements after LBBAP implantation:
- Resolution of nocturnal non-capture episodes
- Restoration of AV synchrony with improved cardiac output
- Narrower paced QRS duration (typically <120-130ms)
- Better exercise tolerance and functional capacity
- Improved quality of life scores
- Prevention of pacing-induced cardiomyopathy
- More physiologic heart rate response to activity
Summary and Key Takeaways
- Don't prioritize device longevity over patient well-being: 60% remaining battery life is not a reason to continue suboptimal pacing if the patient is symptomatic
- Aveir VR limitations are inherent: Nocturnal non-capture and AV dyssynchrony won't improve with time or programming
- LBBAP offers superior physiology: Near-normal cardiac activation, AV synchrony, and stable nocturnal capture
- Consider conversion now if any of the following are present:
- Symptomatic AV dyssynchrony
- NYHA Class II or higher symptoms
- Declining LV function
- Clinically significant nocturnal events
- High pacing burden (>40%)
- Early intervention prevents long-term complications: Chronic RV pacing can lead to pacing-induced cardiomyopathy
Remember:
The goal of cardiac pacing is not just to prevent bradycardia, but to maintain optimal cardiac function and quality of life. When a device is limiting rather than enabling these goals, it's time for reassessment regardless of battery life.